以色列：辉瑞 mRNA 疫苗接种 2 剂后预防冠状病毒感染的有效率为 64%，低于 5 月份的 94%。

[bear88]

不知道国产疫苗产能是否能克服其效率低下的问题，个人当然希望中国疫情得到控制，但如果专制社会因此而得到加强，从历史的经验看，从长远看，大概率是福兮祸所依我

我也希望国产疫苗是有效的，只有中国的疫情不再受到威胁边境才会开放，这样我们才能顺利回去和亲人团聚。但这疫情真的好烦，以为出现曙光的时候总有坏消息紧跟而来，反转又反转没完没了。

 

[米乐米乐]

我也希望国产疫苗是有效的，只有中国的疫情不再受到威胁边境才会开放，这样我们才能顺利回去和亲人团聚。但这疫情真的好烦，以为出现曙光的时候总有坏消息紧跟而来，反转又反转没完没了。

看样子境外是打算与病毒和平共处了，境内做不到的话还是要隔离隔离再隔离的。

 

[阿吾]

看样子境外是打算与病毒和平共处了，境内做不到的话还是要隔离隔离再隔离的。

新冠发展，估计今后就是类似我们现在每年都要来的流感，
那个国家大张旗鼓的隔离流感？

 

[米乐米乐]

新冠发展，估计今后就是类似我们现在每年都要来的流感，
那个国家大张旗鼓的隔离流感？

广州疫情之后国内防控升级了，不知未来如何发展。

 

[周雅]

以色列的这个最新报道是这么说的，

=================
然而，卫生部的数据报告称，该疫苗在预防严重症状和住院方面仍然相当有效。 根据 Ynet 获得的数据，5 月份该数字为 98.2%，而 6 月份则为 93%。

但希伯来大学的研究人员警告说，现在全面说明疫苗在预防住院方面的效果还为时过早。

研究人员写道：“由于公认的严重发病延迟（大约 10 天），目前没有足够的数据来预测当前的感染浪潮在严重病例中的表现。”

他们补充说，虽然预计未来几周严重病例会增加，但来自新加坡和英国的数据表明，辉瑞疫苗在预防最严重的症状方面仍然非常有效。

从同为RNA疫苗的CureVac 三期最终试验结果只有48%，我大概可以推测辉瑞和Modena疫苗对印度新变种的有效防治率一定会下降，问题是下降多少的问题。如果确认只有64%，那是降幅有点过大了，加拿大各省现在除掉口罩会不会像以色列一样再戴回去？英国这样子还要在7月19全部放开，有点搞不懂？

 

[AZURR]

以色列这个报道也说，
Pfizer 疫苗似乎在很大程度上防止了住院和严重病例，但在防止冠状病毒 Delta 变体传播方面的效果明显较差

appears to largely prevent hospitalization and serious cases
这就够了，谁都不能保证自己不感冒不是？

 

[JeSon_Wang]

关键是有效率与各国认可率吧，中国疫苗保护率就不吐槽了，在各国与民众认可率太低了，除了自己吹
辉瑞今年产量30亿剂

何不食肉糜？你在发达国家，公卫体系健全，不用担心疫苗甚至还有得选，其它五六十亿人怎么办？

辉瑞的产能显然是有问题的，我对30亿剂持保留意见，否则加拿大也不用推混打了。

另外，美国疫苗对各国公卫体系要求极高，即使美加也不时能传出xx万剂疫苗因为各种原因报废，众多第三世界国家不具备这个条件。

 

[jongli]

中国现在也承认自身疫苗不行，靠隔离最终会把自己捆死，“作茧自缚”可能是最后的大结局。

 

[windcm]

对照上下图的峰谷，可以看出是俩个星期的滞后，英国最近这个感染爬升是一个多月前开始的，但死亡却看不出任何波动

看来疫情真向着流感化方向走了。。。。这样的话，亚洲国家保持闭关锁国，欧美国家继续开放，彭博社最近修改了疫情评比标准，加入了开放度，亚洲国家排名大幅下滑，回国希望成为泡影。

 

[victorsu99]

从同为RNA疫苗的CureVac 三期最终试验结果只有48%，我大概可以推测辉瑞和Modena疫苗对印度新变种的有效防治率一定会下降，问题是下降多少的问题。如果确认只有64%，那是降幅有点过大了，加拿大各省现在除掉口罩会不会像以色列一样再戴回去？英国这样子还要在7月19全部放开，有点搞不懂？

uk最关注的应该还是住院和重症数据，只要这两项指标没有明显反弹，他们还是会按部就班开放计划，毕竟最怕就是挤兑医疗资源。

 

[Dayday-up]

何不食肉糜？你在发达国家，公卫体系健全，不用担心疫苗甚至还有得选，其它五六十亿人怎么办？

辉瑞的产能显然是有问题的，我对30亿剂持保留意见，否则加拿大也不用推混打了。

另外，美国疫苗对各国公卫体系要求极高，即使美加也不时能传出xx万剂疫苗因为各种原因报废，众多第三世界国家不具备这个条件。

看来土豆预订10亿疫苗还是有先见之明啊

 

[阿吾]

何不食肉糜？你在发达国家，公卫体系健全，不用担心疫苗甚至还有得选，其它五六十亿人怎么办？

辉瑞的产能显然是有问题的，我对30亿剂持保留意见，否则加拿大也不用推混打了。

另外，美国疫苗对各国公卫体系要求极高，即使美加也不时能传出xx万剂疫苗因为各种原因报废，众多第三世界国家不具备这个条件。

pfizer的官宣，
Pfizer and BioNTech expect to manufacture up to 3 billion doses of the COVID-19 vaccine in 2021.

至于中国，看这条消息，

最后还得打洋疫苗

合作15年，看来这个病毒不会走了，到时候跟流感一样，每年都要打。。。 5月9日晚间，复星医药发布公告宣布，控股子公司复星医药产业拟与 BioNTech 投资设立合资公司， 以实现mRNA 新冠疫苗产品的本地化生产及商业化，合资公司的期限自成立之日起15年，初始设立地为中国上海。

forum.iask.ca

Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations | Pfizer

U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022 Doses to be donated to approximately 100 low- and lower middle-income countries including those in the African Union via the COVAX Facility Effort is part of the companies’...

www.pfizer.com

Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations​

Thursday, June 10, 2021 - 02:00am

• U.S. government to purchase at not-for-profit price 200 million doses in 2021 and 300 million in the first half of 2022
• Doses to be donated to approximately 100 low- and lower middle-income countries including those in the African Union via the COVAX Facility
• Effort is part of the companies’ recent pledge of two billion doses to ensure global equitable access to the vaccine

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic. The government will, in turn, donate the Pfizer-BioNTech vaccine doses to low- and lower middle-income countries and organizations that support them.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005930/en/
As part of the plan, the United States will allocate the vaccine doses to 92 low- and lower middle-income countries and economies as defined by Gavi’s COVAX Advance Market Commitment (AMC)
and the 55 member states of the African Union. The U.S. government and the companies will work with COVAX to ensure these vaccines are delivered to the specified countries around the world in a way that is most efficient and equitable.

These doses are part of Pfizer and BioNTech’s previously announced pledge to provide two billion doses of the COVID-19 vaccine to low- and middle-income countries over the next 18 months.

“Our partnership with the U.S. government will help bring hundreds of millions of doses of our vaccine to the poorest countries around the world as quickly as possible. COVID-19 has impacted everyone, everywhere, and to win the battle against this pandemic, we must ensure expedited access to vaccines for all. I want to thank President Biden for his leadership in protecting the least advantaged of our global neighbors,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Fair and equitable distribution has been our North Star since Day One and we are proud to do our part to help vaccinate the world, a massive but an achievable undertaking.”

“As a vaccine developer, we felt the duty to develop a well-tolerated and highly effective vaccine and make it available to as many people worldwide as possible. Today’s agreement underlines that the joint efforts of the private and the public sector are providing solutions to help end this pandemic,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “We are also committed to realizing sustainable solutions by supporting the establishment of manufacturing networks on various continents. Our first step has been the establishment of our Regional Headquarters for south east Asia in Singapore which will also include mRNA manufacturing capacities for regional and global supply. It is our goal to leverage our proprietary mRNA technology to help improve the health of people around the world.”

Deliveries of the 200 million doses will begin in August 2021 and continue through the remainder of the year. The 300 million doses for 2022 will be delivered between January and end of June 2022. The U.S. government also has the option for additional doses in 2022. The plan is to produce the doses being purchased by the U.S. government in Pfizer’s U.S. facilities. Those U.S.-based sites involved in the production of the COVID-19 vaccine include Kalamazoo, MI, Andover, MA, Chesterfield, MO, Groton, CT, and McPherson, KS.

To date, Pfizer and BioNTech have shipped 700 million doses to more than 100 countries or territories around the world. The companies have direct supply agreements in place with 122 countries and discussions are ongoing with many more on the supply of the companies’ COVID-19 vaccine. Based on current projections, Pfizer and BioNTech expect to manufacture up to 3 billion doses of the COVID-19 vaccine in 2021. The production capacity has consistently grown due to continued enhancements to the vaccine’s supply chain, which include expanding existing facilities, adding more suppliers, and bringing on additional Pfizer/BioNTech sites and contract manufacturers around the world to produce the vaccine.

Pfizer and BioNTech have an existing agreement in place to supply vaccine doses to the COVAX Facility, a mechanism established by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and World Health Organization (WHO) that aims to provide governments with early access to a large portfolio of COVID-19 candidate vaccines using a range of technology platforms, produced by multiple manufacturers across the world. Pfizer-BioNTech doses allocated through COVAX have reached countries in every region of the world, including Rwanda, South Korea, Colombia, Peru, Cabo Verde, Tunisia, Angola, West Bank and the Gaza Strip, Moldova, El Salvador, Mongolia, the Maldives, Bosnia and Herzegovina, Georgia, the Ukraine, Bolivia, Kosovo, Bhutan, Bangladesh, Laos, Pakistan and the Philippines. Deliveries to 47 countries and territories around the world are planned through June 2021 as part of the COVAX second round allocation of Pfizer-BioNTech COVID-19 Vaccine doses.

Through both Pfizer and The Pfizer Foundation*, a number of other innovative assistance efforts have been supported, including:

• Working with International Rescue Committee and the Jordanian Ministry of Health to provide essential primary health services and vaccinations to refugees in Jordan;
• Collaborating with the UPS Foundation, which is donating freezers to countries that need assistance with building out their ultra-cold chain capacity; and
• Partnering with Zipline through funding and technical expertise, to design and test a delivery solution that can safely and effectively distribute all COVID-19 vaccines in difficult to reach areas of the countries where it operates.

The U.S. government, the companies and COVAX will finalize the plan and further operational details in the coming weeks.

The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalent in the United States (jointly with Pfizer), Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for use in individuals 12 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564 (b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and Full EUA Prescribing Information available at www.cvdvaccine-us.com

.

 

[阿吾]

从同为RNA疫苗的CureVac 三期最终试验结果只有48%，我大概可以推测辉瑞和Modena疫苗对印度新变种的有效防治率一定会下降，问题是下降多少的问题。如果确认只有64%，那是降幅有点过大了，加拿大各省现在除掉口罩会不会像以色列一样再戴回去？英国这样子还要在7月19全部放开，有点搞不懂？

Modena前几天才刚刚宣布对印度变异有效，没提有效率，
我好像在哪里看的，有人提有效率只有40多%

 

[windcm]

看来土豆预订10亿疫苗还是有先见之明啊

这次土豆总理确实压对了，让没有疫苗生产厂的加拿大，保持在了世界最高疫苗施打量的国家，还有机会搞搞疫苗外交。

 

[JeSon_Wang]

pfizer的官宣，
Pfizer and BioNTech expect to manufacture up to 3 billion doses of the COVID-19 vaccine in 2021.

至于中国，看这条消息，

最后还得打洋疫苗

合作15年，看来这个病毒不会走了，到时候跟流感一样，每年都要打。。。 5月9日晚间，复星医药发布公告宣布，控股子公司复星医药产业拟与 BioNTech 投资设立合资公司， 以实现mRNA 新冠疫苗产品的本地化生产及商业化，合资公司的期限自成立之日起15年，初始设立地为中国上海。

forum.iask.ca

它延迟交货又不是一次两次了，也没人敢去找它索赔。

全产业链国家当然是你需要什么类型疫苗我都有了，怎么可能压宝在BNT。

 

[Dayday-up]

从同为RNA疫苗的CureVac 三期最终试验结果只有48%，我大概可以推测辉瑞和Modena疫苗对印度新变种的有效防治率一定会下降，问题是下降多少的问题。如果确认只有64%，那是降幅有点过大了，加拿大各省现在除掉口罩会不会像以色列一样再戴回去？英国这样子还要在7月19全部放开，有点搞不懂？

One of the big differences between CureVac’s mRNA vaccine and those developed by Pfizer and Moderna is how the mRNA molecules are designed. CureVac has long touted its use of a natural, unmodified form of mRNA, while the other two vaccines rely on several key RNA base modifications.

 

[ww0202]

它延迟交货又不是一次两次了，也没人敢去找它索赔。

全产业链国家当然是你需要什么类型疫苗我都有了，怎么可能压宝在BNT。

全产业链国家？几乎可以肯定没有能力生产高质量LNP传递系统和高纯度假尿苷合酶的能力

 

[AZURR]

全产业链国家？几乎可以肯定没有能力生产高质量LNP传递系统和高纯度假尿苷合酶的能力

基础工业还是很差，是瞟学了一些手艺，但基础的东西没有。30年前造不出轿车发动机，现在第一汽车大国还是造不出拿得出手的发动机。30年前航母漏水没胶补，现在密封材料还是靠进口。造工具的工具还得求东瀛。芯片就不用说了。

 

[victorsu99]

基础工业还是很差，是瞟学了一些手艺，但基础的东西没有。30年前造不出轿车发动机，现在第一汽车大国还是造不出拿得出手的发动机。30年前航母漏水没胶补，现在密封材料还是靠进口。造工具的工具还得求东瀛。芯片就不用说了。

井底之蛙，有时候你把捞出来扔到大洋彼岸，他们还是要找个井口跳下去蹲着。互联网对于他们的意义仅仅在于方便跟其它井蛙互动了，互动之后他们共同的结论是：世界确实就是井口这么大。

 

[gzhou8888]

如果不重病， 不死亡， 那还怕啥呢？人哪有不得病的呢？